Stephen Lin

The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancer

H. Beltran, C. Bandtlow, E. Corey, 2022, Scientific Reports.

Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro‐tumorigenic activity in vivo through a GPI‐anchored receptor, NgR2

L. Languino, A. Kossenkov, Fabio Quaglia, 2024, Journal of extracellular vesicles.

Targeting the αVβ3/NgR2 pathway in neuroendocrine prostate cancer

E. Corey, L. Languino, E. Plow, 2023, Matrix biology : journal of the International Society for Matrix Biology.